Mesenchymal Stem Cells in Cardiology.
Mesenchymal Stem Cells in Cardiology.
复制标题
DOI：
10.1007/978-1-4939-3584-0_4
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Hare JM
中科院分区：
文献类型：
--
作者：
White IA;Sanina C;Balkan W;Hare JM
心血管疾病（CVD）在全球造成的死亡人数超过任何其他单一疾病。仅在美国，每年平均有150万次心肌梗死（心脏病发作），其中约三分之一导致死亡。因此，主要需要开发新的和有效的策略来促进心脏修复。间充质干细胞（MSCs）心肌内移植已成为临床干预和治疗的主要竞争者。MSC是心脏修复的有效介质，因此在临床前和临床试验的发展中是一个有吸引力的工具。MSC能够分泌大量可溶性因子，这些因子已被证明对受损心脏内的致病性心脏重塑、纤维化、免疫激活和心脏干细胞增殖具有作用。MSC也能够分化成心肌细胞、内皮细胞和血管平滑肌细胞，尽管三系分化和旁分泌效应物对心脏修复的相对贡献仍然是积极研究的主题。
Cardiovascular disease (CVD) accounts for more deaths globally than any other single disease. There are on average 1.5 million episodes of myocardial infarction (heart attack) each year in the United States alone with roughly one third resulting in death. There is therefore a major need for developing new and effective strategies to promote cardiac repair. Intramyocardial transplantation of mesenchymal stem cells (MSCs) has emerged as a leading contender in the pursuit of clinical intervention and therapy. MSCs are potent mediators of cardiac repair and are therefore an attractive tool in the development of pre-clinical and clinical trials. MSCs are capable of secreting a large array of soluble factors, which have had demonstrated effects on pathogenic cardiac remolding, fibrosis, immune activation and cardiac stem cell proliferation within the damaged heart. MSCs are also capable of differentiation into cardiomyocytes, endothelial cells and vascular smooth muscle cells, although the relative contribution of trilineage differentiation and paracrine effectors on cardiac repair remains the subject of active investigation.